Stephen Squinto, Life Sciences Private Capital chief investment officer
November 1, 2022 10:51 AM EDTUpdated 02:17 PM
Deals
Bioregnum

JP Mor­gan splash­es in­to the life sci­ences, tap­ping Stephen Squin­to to run ven­ture team with high-pow­ered ad­vi­sors

This morn­ing we’re get­ting an­oth­er clear sign of just how much pri­vate eq­ui­ty has come to love bio­phar­ma dur­ing these stress­ful post-boom times and bat­tered …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

In­side Iso­mor­phic Labs: Demis Has­s­abis’ lab-free vi­sion for biotech’s AI fu­ture

A service from the Financial Times